Breast cancer, metastatic


PALOMA-4: Primary results from a phase 3 trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)

Xu, et al.


PALOMA-4, the largest study to date of a cyclin-dependent kinase 4/6 inhibitor in Asian pts with ABC, confirmed the efficacy and safety of PAL + LET as first-line therapy in postmenopausal Asian women with ER+/HER2– ABC.



Overall Survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs). Final results of the PEARL study.

Martin Jimenez, et al.


Palbociclib + endocrine therapy did not show a statistically superior OS compared to CAP in MBC pts progressing to AIs.



First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies.

M.G. Krebs, et al.


Samuraciclib has demonstrated an acceptable safety profile with evidence of anti-tumour activity.



POSEIDON randomized phase II trial: tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)

Oliveira, et al.


Addition of taselisib to TAM increased PFS in pts with HR+/HER2-neg MBC but the tolerability of the regimen was poor.




A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)

Loibl, et al.


DESIREE met its primary objective and showed that a dose escalation schema of everolimus over three weeks can be successfully used in pts with HR+/HER2- mBC to prevent the onset of mucositis G≥2 without affecting efficacy.